The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
On November 16th, Dr. Jonathan Javitt joined Steve Darling from Proactive to discuss groundbreaking developments in the treatment of suicidal ideation and depression.
NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
NRx Pharmaceuticals, Inc. today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.
NRx Pharmaceuticals, Inc. today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates.
NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals’ wholly owned subsidiary, NeuroRx, Inc.
NRx Pharmaceuticals today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Clinical Development and Medical Affairs. She will lead the Company’s clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director.
